Conrad Fischer

Has grant

Assistant Professor

Barry University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Conrad Fischer is an Assistant Professor at Barry University, United States. His research focuses on the structural biology of SARS-CoV-2, specifically investigating inhibitors of the main protease (Mpro) and developing strategies to counteract viral resistance. Recent publications include studies on nirmatrelvir-resistant variants, novel peptide inhibitors, and the optimization of COVID-19 treatment candidates.

Recent Grants

Grant: Close

Design, Synthesis and Testing of Metabolically Stable Analogs of Apelin-13 for Treatment of Cardiovascular Disease

Open Date: 2016-01-01

Close Date: 2018-12-31

Grant: Close

Structure and Mechanism of Hyoscyamine-6ß-Hydroxylase (H6H), an Enzyme that converts (-)-Atropine to Scopolamine: Prospects for Aerobic Epoxidation of Non-Activated Alkane Chains

Open Date: 2014-01-01

Close Date: 2015-12-31

Articles (11)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (7)

Howard S. Young

University of Alberta

CANADA

View details

Tess Lamer

University of Alberta

CANADA

View details

Xavier Iturrioz

université paris saclay cea cnrs institut de biologie intégrative de la cellule (i2bc) gif‐sur‐yvette 91198 france

FRANCE

View details

Joanne Lemieux

Professor

University of Alberta

CANADA

View details

James A. Nieman

University of Alberta

CANADA

View details

Muhammad Bashir Khan

University of Alberta

CANADA

View details

John Vederas

Professor

University of Alberta

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Conrad Fischer

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (11)

Structural insights into the nirmatrelvir-resistant SARS-CoV-2 Mpro L50F/E166A/L167F triple mutant-inhibitor-complex reveal strategies for next generation coronaviral inhibitor design

Peptide Aldehydes Incorporating Thiazol-4-yl Alanine Are Potent In Vitro Inhibitors of SARS-CoV-2 Main Protease

A Structural Comparison of Oral SARS-CoV-2 Drug Candidate Ibuzatrelvir Complexed with the Main Protease (Mpro) of SARS-CoV-2 and MERS-CoV

Assessment of optimized FRET substrates as universal corona- and picornavirus main protease substrates for screening assays

SARS-CoV-2 Mpro Inhibitors: Achieved Diversity, Developing Resistance and Future Strategies

Improved SARS-CoV-2 M<sup>pro</sup> inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies.

N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 M<sup>pro</sup> Dimer.

Metabolically stable apelin-analogues, incorporating cyclohexylalanine and homoarginine, as potent apelin receptor activators

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.

Optimizing PEG-Extended Apelin Analogues as Cardioprotective Drug Leads: Importance of the KFRR Motif and Aromatic Head Group for Improved Physiological Activity.

A patent review of apelin receptor (APJR) modulators (2014-2019)

Collaborators (7)

Howard S. Young

Tess Lamer

Xavier Iturrioz

Joanne Lemieux

James A. Nieman

Muhammad Bashir Khan

John Vederas

Make your next move.